Systemic mastocytosis (SM) is a rare hematological neoplasm. Advanced systemic mastocytosis can be sub-classified into either aggressive SM, SM with an associated hematological neoplasm (SM-AHN) or mast cell leukemia.

In this insightful podcast, Deepti Radia, MBBS, MRCPI, FRCPath, of Guy’s and St Thomas’ Hospital NHS Foundation Trust, London UK, firstly discusses the management of patients with systemic mastocytosis with associated hematological neoplasm. Dr Radia also details the current treatment options for this condition, as well as on-going clinical trials. Additionally, Dr Radia discusses the management of hematological oncology patients during the COVID-19 pandemic.

The post Systemic mastocytosis: current landscape, novel agents and COVID-19 appeared first on VJHemOnc.